The CDC is responding to criticism over its handling of the COVID-19 pandemic, monkeypox and other public health threats.Pfizer and German partner BioNTech have submitted their new COVID-19 booster – that targets the omicron subvariant BA.
The company has tested the BA.5-specific vaccine only on mice, so far, and is relying on data from both the BA.1 human trials and the BA.5 mice trials for their submission for authorization. “To rely only on mouse data would be unprecedented in my knowledge and would certainly raise eyebrows,” said John Moore, a vaccine and virology expert at Weill Cornell Medicine in New York. “It doesn’t mimic the human situation,” where many people were vaccinated more than a year ago and have since been boosted.
But Moore isn't convinced the data will show the BA.5 booster working significantly better than the BA.1 booster, or even the original booster. The public expects the new booster to prevent more infections, he said, but it will probably be only marginally more protective.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: TIMEHealth - 🏆 121. / 63 Read more »
Source: WSJhealth - 🏆 413. / 53 Read more »
Source: abc7newsbayarea - 🏆 529. / 51 Read more »
Source: ABC7Chicago - 🏆 284. / 63 Read more »
Source: AKNewsNow - 🏆 460. / 53 Read more »
Pfizer seeks OK of updated COVID vaccine booster for fallThe U.S. has a contract to buy 105 million of the updated Pfizer doses as soon as health authorities greenlight them, and the company said doses are ready to ship. Nobody wants them. So why are they buying them? Oh wait, I know.. 💵 Whatever you do, don’t get vaccinated
Source: 13WHAM - 🏆 256. / 63 Read more »